The Mid-Term Clinical Follow-Up Using Drug-Eluting Balloons on Tibial Artery “De Novo” Lesions in Patients With Critical Limb Ischemia

Abstract

Rationale:

Restenosis due to intimal hyperplasia (IH) is a major clinical issue that affects the success of lower limb endovascular surgery. After 1 year, restenosis occurs in 40% to 60% of the treated vessels. The possibility to reduce IH using local antiproliferative drugs, such as taxols, has been the rationale for the clinical applications of drug-eluting stents and drug-eluting balloons (DEBs). The purpose of this study was to evaluate the clinical and instrumental efficacy of DEBs versus simple percutaneous transluminal angioplasty (PTA) in patients affected by chronic limb ischemia (CLI) with tibial artery “de novo” lesions.

Methods:

A retrospective analysis was performed and included all consecutive patients who underwent endovascular treatment for CLI in our centers between January 2011 and March 2013. Inclusion criteria were (1) “de novo” tibial artery stenosis and (2) Rutherford class >4. Lesions were further divided by TransAtlantic Inter-Societal Consensus (TASC) classification into groups A, B, C, and D.

Results:

Between January 2010 and March 2013, a total of 138 patients underwent simple PTA or DEB for CLI, and the groups were clinically and demographically homogenous. We decided to use DEBs in 70 cases. An improvement in the Rutherford Scale in cumulative and single TASC lesions classification was better in the DEB group (74% vs 51%; P = .024) at 24 months than in the PTA group. In the DEB group, the increase in ankle–brachial index was significantly higher than in the PTA group (P = .039).

Conclusions:

Our experience in addition to the existing literature supports the use of DEB in patients with CLI Rutherford class >3.

Keywords

intimal hyperplasia drug-eluting balloon restenosis

Get full access to this article

View all access options for this article.

References

TASC Steering Committee, Jaff

White

Hiatt

. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II). J Endovasc Ther. 2015;22(5):663–677. doi: 10.1177/1526602815592206.

Norgren

Hiatt

Dormandy

Nehler

Harris

Fowkes

; TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(suppl s):s5–s67.

Karnabatidis

Spiliopoulos

Diamantopou-los

. Primary everolimus-eluting stenting versus balloon angioplasty with bailout bare metal stenting of long infrapopliteal lesions for treatment of critical limb ischemia. J Endovasc Ther. 2011;18(1):1–12.

Ansel

Lumsden

. Evolving modalities for femoropopliteal interventions. J Endovasc Ther. 2009;16(2 suppl 2):82–97.

Geraghty

Mewissen

Jaff

Ansel

; VIBRANT Investigators. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg. 2013;58(2):386–395.

Unverdorben

Vallbracht

Cremers

. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119(23):2986–2994.

TASC. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Eur J Vasc Endovasc Surg. 2000;19(suppl a):si–xxviii, s1–s250.

Troutman

Madden

Dougherty

Calligaro

. Duplex ultrasound diagnosis of failing stent grafts place for occlusive disease. J Vasc Surg. 2014;60(6):1580–4.

Antoniou

Chalmers

Georgiadis

. Review A meta-analysis of endovascular versus surgical reconstruction of femoropopliteal arterial disease. J Vasc Surg. 2013;57(1):242–253.

10.

Hirsch

Haskal

Hertzer

. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Circulation. 2006;113(1):1474–1547.

11.

Scheinert

Duda

Zeller

. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization. JACC Cardiovasc Interv. 2014;7(1):10–19.

12.

Hankey

Eikelboom

. Homocysteine and vascular disease. Lancet. 1999;354(9176):407–413.

13.

Tepe

Laird

Schneider

; IN.PACT SFA Trial Investigators. Trial Investigators. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131(5):495–502.

14.

Schonbeck

Libby

. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation. 2004;109(21 suppl 1):ii18–ii26.

15.

Tolva

Casana

Lonati

. Percutaneous transluminal angioplasty improves glucose control and quality of life in patient with critical limb ischemia. Eur Rev Med Pharmacol Sci. 2012;16(15):2082–2087. PMID:23280023.

16.

Liistro

Grotti

Porto

. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv. 2013;6(12):1295–1302.

17.

Zeller

Rastan

Macharzina

. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions. J.Endovasc Ther. 2014.21(3):359–368.

18.

Fanelli

Cannavale

Boatta

Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endovasc Ther. 2012,19(5):571–558.

19.

Ridker

Buring

Rifai

Cook

. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA. 2007;297(6):611–619.

20.

Herten

Torsello

Schönefeld

Imm

Osada

Stahlhoff

. Drug-eluting balloons for femoropopliteal lesions show better performance in de novo stenosis or occlusion than in restenosis. J Vasc Surg. 2015;61(2):394–399.

21.

Molloy

Nasim

London

. Percutaneous transluminal angioplasty in the treatment of critical limb ischemia. J Endovasc Ther. 2003;10(2):298–303.

22.

Huang

Schneider

. Endovascular intervention for tibial artery occlusive disease in patients with critical limb ischemia. Semin Vasc Surg. 2014;27(1):38–58.

23.

Bleda

de Haro

Varela

Acin

. C-reactive protein and endovascular treatment of lower limb peripheral artery disease: an independent prognostic factor. J Endovasc Ther. 2015;22(2):233–239.

24.

Derubertis

Pierce

Ryer

Trocciola

Kent

Faries

. Reduced primary patency rate in diabetic patients after percutaneous intervention results from more frequent presentation with limb threatening ischemia. J Vasc Surg. 2008;47(1):101–108.

25.

Tolva

Mazzola

Zerbi

. A successful experimental model for intimal hyperplasia prevention using a Resveratrol eluting balloon. J Vasc Surg. 2016;63(3):788–794.